Last reviewed 2026-04-23 · How we verify

Laif® 900, BAY98-7108

Bayer · Phase 3 active Small molecule

Laif® 900, BAY98-7108 is a Herbal antidepressant / Phytopharmaceutical Small molecule drug developed by Bayer. It is currently in Phase 3 development for Mild to moderate depression.

Laif 900 is a standardized St. John's Wort extract that modulates serotonin and other neurotransmitter systems to improve mood in depression.

Laif 900 is a standardized St. John's Wort extract that modulates serotonin and other neurotransmitter systems to improve mood in depression. Used for Mild to moderate depression.

At a glance

Generic name	Laif® 900, BAY98-7108
Sponsor	Bayer
Drug class	Herbal antidepressant / Phytopharmaceutical
Target	Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)
Modality	Small molecule
Therapeutic area	Psychiatry / Mental Health
Phase	Phase 3

Mechanism of action

Laif 900 contains hyperforin and hypericin as active constituents derived from St. John's Wort (Hypericum perforatum). These compounds inhibit the reuptake of serotonin, norepinephrine, and dopamine, and may also modulate other neurotransmitter pathways. The extract is used as a phytopharmaceutical treatment for mild to moderate depressive symptoms.

Approved indications

Mild to moderate depression

Common side effects

Photosensitivity
Gastrointestinal upset
Headache
Dizziness
Drug interactions (CYP3A4 induction)

Key clinical trials

Study to Learn About Relapse Prevention of Hypericumextract (a Drug Based on the Plant St. John Wort) in Outpatients Suffering From Moderate Depressive Episodes (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Laif® 900, BAY98-7108 CI brief — competitive landscape report
Laif® 900, BAY98-7108 updates RSS · CI watch RSS
Bayer portfolio CI

Frequently asked questions about Laif® 900, BAY98-7108

What is Laif® 900, BAY98-7108?

Laif® 900, BAY98-7108 is a Herbal antidepressant / Phytopharmaceutical drug developed by Bayer, indicated for Mild to moderate depression.

How does Laif® 900, BAY98-7108 work?

Laif 900 is a standardized St. John's Wort extract that modulates serotonin and other neurotransmitter systems to improve mood in depression.

What is Laif® 900, BAY98-7108 used for?

Laif® 900, BAY98-7108 is indicated for Mild to moderate depression.

Who makes Laif® 900, BAY98-7108?

Laif® 900, BAY98-7108 is developed by Bayer (see full Bayer pipeline at /company/bayer).

What drug class is Laif® 900, BAY98-7108 in?

Laif® 900, BAY98-7108 belongs to the Herbal antidepressant / Phytopharmaceutical class. See all Herbal antidepressant / Phytopharmaceutical drugs at /class/herbal-antidepressant-phytopharmaceutical.

What development phase is Laif® 900, BAY98-7108 in?

Laif® 900, BAY98-7108 is in Phase 3.

What are the side effects of Laif® 900, BAY98-7108?

Common side effects of Laif® 900, BAY98-7108 include Photosensitivity, Gastrointestinal upset, Headache, Dizziness, Drug interactions (CYP3A4 induction).

What does Laif® 900, BAY98-7108 target?

Laif® 900, BAY98-7108 targets Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT) and is a Herbal antidepressant / Phytopharmaceutical.

Drug class: All Herbal antidepressant / Phytopharmaceutical drugs
Target: All drugs targeting Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT)
Manufacturer: Bayer — full pipeline
Therapeutic area: All drugs in Psychiatry / Mental Health
Indication: Drugs for Mild to moderate depression
Compare: Laif® 900, BAY98-7108 vs similar drugs
Pricing: Laif® 900, BAY98-7108 cost, discount & access